文献速递毛发、甲与色素性疾病

美国成人扁平苔藓毛囊炎患病率与治疗模式

Prevalence and Treatment Patterns in Patients With Lichen Planopilaris.
PubMed 文献 · JAMA Dermatol · 2024-01-01

这项横断面研究利用Explorys数据库分析美国成人扁平苔藓毛囊炎(LPP)的患病率和皮肤科医生处方治疗模式。标准化患病率为每10万人13.4例(95%CI 11.7-15.1)。多数患者接受至少一种药物治疗,最常用病灶内和局部糖皮质激素,部分患者需持续、切换或联合治疗。

要点

  • 美国成人LPP标准化患病率为13.4/10万(95%CI 11.7-15.1)。
  • 64.1%患者接受至少一种药物治疗,最常用病灶内和局部糖皮质激素。
  • 部分患者治疗持续超过1年、切换或联合治疗,提示需优化药物选择。

核心结论

  • 美国成人LPP标准化患病率为13.4/10万(95%CI 11.7-15.1)。
  • 多数LPP患者接受药物治疗,且不少患者需多种治疗、切换或联合治疗。

研究设计与样本

  • 横断面研究,使用Explorys数据库。
  • 患病率分析采用15%随机样本,纳入2017至2019年诊断为LPP的美国成人。
  • 治疗分析纳入2016至2020年诊断为LPP且在诊断后第一年内有皮肤科就诊的所有患者。

主要发现

  • 患病率分析纳入1 466 832例 eligible 患者,其中241例诊断为LPP(222例[92.1%]为女性;中位[IQR]年龄64[54-73]岁)。
  • 治疗分析纳入991例LPP患者(907例[91.5%]为女性;中位[IQR]年龄60[47-69]岁)。
  • 635例(64.1%)接受至少一种药物治疗,最常用病灶内糖皮质激素(370例[37.3%])和局部糖皮质激素(342例[34.5%]),其次为多西环素(104例[10.5%])和羟氯喹(72例[7.3%])。
  • 病灶内糖皮质激素治疗超过1年者71/200例(35.5%),羟氯喹超过1年者7/29例(24.1%)。
  • 1年内切换治疗:首次处方病灶内糖皮质激素者32/254例(12.6%),首次处方局部糖皮质激素者44/194例(22.7%);联合2种或3种治疗者分别为137例(13.8%)和74例(7.5%)。

临床怎么用

  • LPP在US成人中并不罕见,临床需关注其患病情况。
  • 多数患者需药物治疗,病灶内和局部糖皮质激素是常用选择。
  • 部分患者需长期、切换或联合治疗,提示应个体化选择药物并探索更优方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lichen planopilaris (LPP) is a form of scarring alopecia associated with progressive, permanent hair loss. Symptoms range from burning pain to itching, also carrying substantial psychological morbidity. Yet, disease characteristics, pathophysiology, and effective treatment data are limited, making treatment a challenge. OBJECTIVE: To describe the prevalence and dermatologist-prescribed treatment patterns of LPP among US adults. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used the Explorys database. The prevalence analysis used a 15% random sample and identified US adults with LPP diagnoses between 2017 and 2019. The LPP treatment analysis included all patients with LPP diagnoses between 2016 and 2020 and a dermatologist encounter in the first year after diagnosis. Data were analyzed from January 2023 to April 2023. MAIN OUTCOMES AND MEASURES: The main outcomes of the prevalence analysis were the crude and standardized prevalence estimates of US adults with LPP across age, sex, and racial groups. The main outcomes of the treatment analysis were the frequency of LPP treatments within 1 year of diagnosis, and the number of patients who continued treatment beyond 1 year, switched treatments, and combined treatments. RESULTS: Among 1 466 832 eligible patients analyzed for prevalence, 241 patients had an LPP diagnosis (222 [92.1%] female; median [IQR] age, 64 [54-73] years). Standardized overall prevalence was 13.4 per 100 000 (95% CI, 11.7-15.1). In the treatment analysis, 991 patients had an LPP diagnosis (907 [91.5%] female; median (IQR) age, 60 [47-69] years). Most received at least 1 type of medication (635 [64.1%]), most frequently intralesional corticosteroids (370 [37.3%]) and topical corticosteroids (342 [34.5%]), followed by doxycycline (104 [10.5%]) and hydroxychloroquine (72 [7.3%]). Treatment continued beyond 1 year in 71 of 200 patients (35.5%) prescribed intralesional corticosteroids and 7 of 29 patients (24.1%) prescribed hydroxychloroquine. Treatment switching at 1 year occurred in 32 of 254 patients (12.6%) first prescribed an intralesional corticosteroid and in 44 of 194 (22.7%) first prescribed a topical corticosteroid. Combinations of 2 or 3 treatment types were given to 137 (13.8%) and 74 (7.5%) patients, respectively. CONCLUSIONS AND RELEVANCE: This cross-sectional study reported prevalence and treatment patterns for US adults with LPP in a representative sample. Most patients with LPP received treatment, and many received multiple treatment types and switched treatments, suggesting further research into medication selection offers clinical benefit.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Pelet Del Toro N, Strunk A, Garg A, et al. Prevalence and Treatment Patterns in Patients With Lichen Planopilaris. JAMA Dermatol. 2024. PMID: 38865116. doi:10.1001/jamadermatol.2024.1445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。